Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.
Cancers
View this publicationCancers
View this publicationCellular and molecular life sciences : CMLS
View this publicationCell reports
View this publicationJournal of lipid research
View this publicationNature metabolism
View this publicationLa Radiologia medica
View this publicationJournal of clinical medicine
View this publicationBioinformatics advances
View this publicationInternational journal of cardiology
View this publicationNature communications
View this publication